Introduction
Myasthenia gravis is a T-cell-dependent, antibodymediated, complement-involved, organ-specific autoimmune disease, characterized by muscle fatigability, which develops as a result of impaired neuromuscular transmission. [1] [2] [3] [4] [5] Abnormal development of high-affinity autoantibody-producing B cells in the germinal centres is a central feature of myasthenia gravis. 6 Experimental autoimmune myasthenia gravis (EAMG) has been recognized as the animal model for myasthenia gravis. It can be induced by a synthetic peptide corresponding to regions 97-116 of the rat AChR a-subunit (R97-116 peptide). 1, [7] [8] [9] [10] Germinal centres (GCs) are temporary structures in peripheral lymphatic tissue and play a crucial role in affinity maturation by somatic hypermutation and isotype switching. [11] [12] [13] Follicular helper T cells (Tfh cells) are essential for helping cognate B cells form and maintain the GC reaction. [14] [15] [16] [17] [18] Aberrant changes in the number or function of Tfh cells have been correlated with the pathogenesis and severity of autoimmune disease. 16, [19] [20] [21] [22] It was reported that adoptive transfer of Tfh cells led to GC formation. 16 How to limit the numbers of Tfh cells within GCs has become the focus of preventing the emergence of autoantibody. 16, 23 Follicular regulatory T (Tfr) cells, which share phenotypic characteristics of Tfh and Foxp3 + regulatory T (Treg) cells, are required to suppress T-cell proliferation and Tfh numbers, and control GC B-cell selection. 24 Tfr cells are crucial for the development of self-tolerance and have become the major focus in many studies interpreting the pathogenesis of autoimmune disease. Tfr cells derive from Treg cell precursors, and concurrently express B-lymphocyte-induced maturation protein 1 (Blimp1) and B-cell lymphoma 6 (Bcl-6). [24] [25] [26] [27] Bcl-6 is essential for Tfr cell formation, and Blimp1 regulates the size of the Tfr cell population. Blimp1 is required for the differentiation of B cells and T cells, and it has been identified as an essential regulator of T-cell homeostasis and activation. [28] [29] [30] It has been shown that loss of Blimp1 could double the proportion of Tfr cells without any alteration in the proportion of Tfh cells. 24 If deficiency of Blimp1 results in greater suppressive ability of Tfr cells, then Blimp1 will become an important target for the treatment of myasthenia gravis.
However, little is known about the effect of loss of Blimp1 on the function of Tfr cells. In this study, we demonstrated that Blimp1-deficient Treg cells differentiated into more Tfr cells than did wild-type Treg cells in vitro. Blimp1-deficient Tfr cells in the spleen had a decreased ability to suppress both the activation of Tfh cells and antibody production in vitro. In addition, we found that adoptive transfer of Blimp1-deficient Tfr cells could ameliorate clinical myasthenic symptoms in mice with ongoing EAMG, although this was inferior to wildtype Tfr cells.
Materials and methods

Animal and antigen
Female C57BL/6 mice (6-8 weeks of age) were purchased from Laboratory Animal Co. Ltd. of Slack King in Hunan Province (license no. SCXK 2011-0003). Animals were housed at the animal facility of the Division of Animal Care at Central South University. All animal experiments were approved by the Ethics Committee of the institute and performed in accordance with the Principles of Laboratory Animal Care of Xiangya Hospital. Animals were killed after deep anaesthesia obtained by carbon dioxide; low-grade anaesthesia with 4% chloral hydrate (SigmaAldrich, St Louis, MO) administered intraperitoneally was used for immunization and treatments.
The antigen used to induce EAMG was a synthetic peptide corresponding to region a 97-116 of the rat AChR a-subunit (R97-116). The peptides R97-116 (DGDF AIVK FTKV LLDY TGHI) were synthesized by GL Biochem Ltd., Shanghai, China (Lot number: P140924-MJ148487). Peptides were purified by reverse-phase highperformance liquid chromatography, and their synthesis was confirmed by mass spectroscopy.
Synthesis of siRNA-Blimp1
Cholesterol-conjugated Blimp1 small interfering RNA (sense: 5 0 -CCCGAAUCAAUGAAGAAAUTT-3 0 , antisense: 5 0 -AUUUCUUCAUUGAUUCGGGTT-3 0 ), its negative control and Cy3-siRNA were from RiboBio (Guangzhou, China).
Induction and clinical assessment of EAMG
Mice were randomly divided into two groups. Mice in the EAMG group were immunized by subcutaneous injection in the hind footpads and the shoulders with 50 lg AChR R97-116 peptide in 200 ll CFA (Sigma) supplemented with 1 mg of Mycobacterium tuberculosis strain H37RA (Difco Laboratories, Detroit, MI) on day 0 and boosted on days 30 and 60 with the same peptide in CFA. The control group was immunized with CFA emulsion, containing phosphate-buffered saline (PBS) instead of the peptide ( Figure S1 ).
Clinical scoring was based on the presence of tremor, hunched posture, muscle strength, fatigability, and was assessed after paw exercise (repetitive paw grips on the cage grid for 30 times). Disease severity was expressed as follows: grade 0, normal muscle strength and activities; grade 1, normal at rest, mildly decreased activity (characteristically shown by hunchback posture, and weak grip or backward movement), more evident at the end of exercise; grade 2, clinical signs present at rest (tremor, hunchback posture and weak grip or backward movement); grade 3, severe clinical signs present at rest, moribund with or without closure or secretions of the eyes; grade 4, dead. Mice with intermediate signs were assigned scores of 0Á5, 1Á5, 2Á5 or 3Á5.
Cell culture in vitro
To explore the effect of Blimp1 on the homeostasis and function of Tfr cells, spleen cells were harvested from the wild-type C57BL/6 mice aged 6-8 weeks. + immunomagnetic beads from spleen cells, and then were sorted to a purity of 99% on a FACSAria II (BD Biosciences, San Diego, CA). B cells were then purified with immunomagnetic beads from the spleen cells of mice with EAMG (grade ≥ 1.5),and the purity of B cells was up to 98.5% ( Figure S2 ). 2 9 10 5 Treg cells from the spleen of wild-type mice were plated with 2 lg/ml soluble anti-CD3 (BD Biosciences) and 100 U/ml interleukin-2 (eBioscience, San Diego, CA), and then were transiently transfected by siRNA-Blimp1 (400 nM final) and siRNAnegative control (NC) (400 nM final). After 6 hr, fresh complete RPMI-1640 was added supplemented with 20% fetal bovine serum, 2 lg/ml soluble anti-CD3 and 100U/ml interleukin-2. After 24 and 48 hr, cells were harvested for the detection of transcription and expression of Blimp1. After 5 days, cells were collected to identify the frequency of Tfr cells by flow cytometry. 1 9 10 5 Tfr cells from the spleens of wild-type mice were plated with 2 lg/ml soluble anti-CD3 (BD Bioscience), and were then transiently transfected by siRNA-Blimp1 (400 nM final) and siRNA-NC (400 nM final). After 6 hr, fresh complete RPMI-1640 supplemented with 20% fetal bovine serum and 2 lg/ml soluble anti-CD3. Twenty-four hours after transient transfection of Tfr cells, B cells from EAMG mice were plated with Tfh cells and/or transfected Tfr cells pooled from wild-type C57BL/6 mice and 2 lg/ml soluble anti-CD3 and 5 lg/ml anti-IgM (BD Bioscience). After 4 days, supernatants were collected for antibody analysis by ELISA, and cells were harvested to identify the frequency of B-cell subsets and the surface activation molecules on B cells by flow cytometry.
Adoptive transfer
The Tfr cells were pre-purified with CD4 + immunomagnetic beads from spleen cells, and then were sorted to a purity of 99% on a FACSAria II (BD Biosciences). Then, 2 9 10 5 T fr cells from the spleens of wild-type mice were plated with soluble anti-CD3 (as described above), and then were transiently transfected by siRNA-Blimp1 and siRNA-NC. 24 hr after transient transfection, Tfr cells were used for adoptive transfer.
On day 70 (after the first immunization) the EAMG mice (Grade ≥ 1.5) were divided randomly into three groups: EAMG-PBS, EAMG-siBlimp1-Tfr and EAMGsiNC-Tfr groups. The mice in the EAMG-siBlimp1-Tfr group were treated with siRNA-Blimp1-Tfr cells (2 9 10 5 /200 ll) by tail injection intravenously every 5 days for a total of three injections (days 0, 5, 10). The mice were treated with siRNA-NC-Tfr cells (2 9 10 5 /200 ll) in the EAMG-siNC-Tfr group and PBS (200 ll) in the EAMG-PBS group using the same method, and clinical assessment and myasthenic scoring of the mice in each group were recorded every day. At the same time the serum specimens were collected to detect the secretion level of anti-R97-116 IgG by ELISA. At day 15 after the first treatment on day 0, the mice were killed and spleen cells were collected. Frequencies of B-cell subsets and T-cell subsets were detected by flow cytometry. The expression of key protein in the mitogen-activated protein kinase (MAPK) pathway and AKT pathway in mouse B cells was detected by Western blot. In the B-cell group it was 11Á82 AE 1Á27%, in the co-culture group of Tfh + B cells it was 22Á72 AE 1Á94%, in the co-culture group of Tfr + B cells it was 12Á06 AE 0Á94%, in the co-culture group of Tfr + Tfh + B cells it was 10Á92 AE 0Á99%, and in the co-culture group of siBlimp1-Tfr + Tfh + B cells it was 13Á3 AE 1Á06%. (b) Flow cytometry analysis of CD45R + CD27 + CD44 + memory B cells. In the B-cell group it was 12Á54 AE 1Á61%, in the co-culture group of Tfh + B cells it was 33Á26 AE 1Á68%, in the co-culture group of Tfr + B cells it was 11Á92 AE 1Á29%, in the co-culture group of Tfr + Tfh + B cells it was 31Á58 AE 0Á90%, and in the co-culture group of siBlimp1-Tfr + Tfh + B cells it was 33Á0 AE 1Á02%. (c) There were no significant differences in the expression of CD40 in all groups. (d) Flow cytometry analysis of CD80 showed that in the B-cell group it was 40Á64 AE 1Á56%, in the co-culture group of Tfh + B cells it was 44Á94 AE 1Á36%, in the co-culture group of Tfr + B cells it was 39Á74 AE 0Á69%, in the co-culture group of Tfr + Tfh + B cells it was 41Á32 AE 1Á18%, in the co-culture group of siBlimp1-Tfr + Tfh + B cells was 40Á88 AE 1Á33%. As for CD86 (e), in the B cells group it was 84Á64 AE 1Á61%, in the co-culture group of Tfh + B cells it was 94Á56 AE 1Á58%, in the co-culture group of Tfr + B cells it was 84Á42 AE 1Á03%, in the co-culture group of Tfr + Tfh + B cells it was 83Á08 AE 1Á82%, in the co-culture group of siBlimp1-Tfr + Tfh + B cells it was 86Á14 AE 1Á63% (*P < 0Á05 
Flow cytometry
Cells were resuspended in staining buffer (PBS containing 1% fetal calf serum and 2 mM EDTA) and were stained with the following directly labelled antibodies: FITC-conjugated anti-mouse CD4, allophyocyanin (APC) -conjugated anti-mouse CXCR5, phycoerythrin (PE) -Cy7-conjugated anti-mouse ICOS, PE-conjugated antimouse Foxp3, PE-conjugated anti-mouse GITR, FITCconjugated anti-mouse CD45R, APC-conjugated anti-mouse CD27, PE-conjugated anti-mouse CD138, PEconjugated anti-mouse CD44, PE-conjugated anti-mouse CD40, PE-conjugated anti-mouse CD80, PE-conjugated anti-mouse CD86, APC-conjugated anti-mouse CD25, APC-conjugated anti-mouse CD3e, PE-conjugated antimouse interferon-c, PE-conjugated anti-mouse interleukin-4, PE-conjugated anti-mouse interleukin-17A, PEconjugated anti-mouse CD 19, PE-Cy7-conjugated antimouse CD5, PE-conjugated anti-mouse CD25, PE-conjugated anti-mouse CD69, PE-conjugated anti-mouse CD71. For nuclear transcription factor staining, a Foxp3 Fix/Perm kit (eBioscience) was used after surface staining. For cellular staining, Fixation/Permeabilization kit (BD Bioscience) was used after surface staining. All flow cytometry data were analysed with an LSR II (BD Bioscience) with standard filter sets and were further analysed with FLOWJO software (TreeStar, Ashland, OR).
Enzyme-linked immunosorbent assay
To detect the production of anti-R97-116 IgG, ELISA was performed with an anti-mouse IgG (Immunology Consultants Laboratories, Portland, OR), as indicated by the instructions. Optical density (OD) was measured at 450 nm using an automated microplate ELISA reader. Results are expressed as OD at 450 nm.
Western blot analysis
Purified B cells from spleen of the three EAMG groups were prepared and analysed by SDS-PAGE. The following primary antibodies were used: rabbit antiphospho-JNK (Thr183/Tyr185) antibody, rabbit anti-phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) antibody, rabbit anti-phospho-P38 (Thr180/Tyr182) anti body, rabbit anti-phospho-Akt (Ser473) antibody and rabbit anti-Akt antibody (Cell Signal Technology, Beverley, MAUSA). The quantification of the bands was done by densitometry analysis.
Histological staining
Tissue samples from the spleen were immersed in 4% paraformaldehyde and embedded in paraffin wax. Sections were processed and stained with haematoxylin & eosin (H&E) to assess the number and size of GCs. Each sample was sliced into 2-mm sections, and then was visualized using fluorescence microscopy (Nikon, Tokyo, Japan).
For GL7 staining, 4-lm sections were prepared from paraffin-embedded tissues. After deparaffinization, endogenous peroxidase was quenched with 0Á3% H 2 O 2 in 60% methanol for 30 min. After 30-min blockade with 10% goat serum, anti-rat GL7 monoclonal antibody (1 : 100 dilution in PBS; eBioscience) was incubated overnight at 4°, followed by a second incubation with rabbit anti-rat IgG-horseradish peroxidase for another 2 hr. Finally, DAB was used as a substratechromogen that produces a brown colour in GL7-positive cells. Sections were counterstained for 1 min with haematoxylin.
Statistical analysis
The data were presented as the mean AE standard deviation. All statistical analyses were carried out with the Statistical Package for Social Science, version 13.0 (SPSS Inc., Chicago, IL). Multiple comparisons were analysed using one-way analysis of variance. P-values of < 0Á05 were considered statistically significant. In the B cells group it was 3Á17 AE 0Á08 (OD 450 nm), in the co-culture group of Tfh + B cells it was 3Á88 AE 0Á06, in the co-culture group of Tfr + B cells it was 3Á17 AE 0Á08, in the co-culture group of Tfr + Tfh + B cells it was 3Á15 AE 0Á07, and in the co-culture group of siBlimp1-Tfr + Tfh + B cells it was 3Á24 AE 0Á05 (*P < 0Á05). We found that plasma cells, memory B cells and the expression of CD80 and CD86 were significantly increased when B cells were cultured with Tfh cells (Fig. 2) . Plasma cells and the expression of the CD80 and CD86 were obviously decreased in the presence of Tfr cells. The inhibition of the Blimp1-deficient Tfr cells were less than negative control Tfr cells.
B cells produced large amounts of IgG when cultured with Tfh cells (Fig. 3) . When we added the Tfr cells to the wells along with the Tfh cells, the production of IgG dramatically decreased. Blimp1-deficient Tfr cells suppress IgG production less than negative control Tfr cells did at ratios of Tfr cells to Tfh cells of 1 : 1. This is consistent with the change of plasma cells.
Reduced suppression of Blimp1-deficient Tfr cells in vivo
The results described above suggest that Blimp1 controls the activation of Tfr cells in vitro. To demonstrate that the deficiency of Blimp1 could attenuate the suppression of Tfr in vivo, Blimp1-deficient Tfr cells and negative control Tfr cells were transferred into EAMG mice (Fig. 4a) . By 15 days after first transfer, we observed less amelioration of the clinical severity in the EAMG mice that received Blimp1-deficient Tfr cells than in the group treated with negative control Tfr cells (Fig. 4b) . As expected, compared with the EAMG mice treated with negative control Tfr cells, the level of anti-R97-116 IgG was significantly higher in the EAMG mice that received Blimp1-deficient Tfr cells (Fig. 4c) . 
Blimp1 regulates Tfr cell activation in vivo
We next investigate the suppressive ability of Blimp1-deficient Tfr cells in vivo. Negative control Tfr cells inhibited the generation of plasma cells (Fig. 5a ), memory B cells (Fig. 5b ), B1 cells (Fig. 5c ), Th1 cells (Fig. 6a ), Th17 cells (Fig. 6c ) and Tfh cells (Fig. 7b) , in the spleen to a greater extent than did Blimp1-deficient Tfr cells in EAMG mice. Meanwhile, the proportions of Treg cells (Fig. 6d ), Tfr cells (Fig. 7a ) and Th2 cells (Fig. 6b) were significantly higher in the EAMG mice that received negative control Tfr cells than in the group transferred with Blimp1-deficient Tfr cells. Together these data showed that Blimp1 deficiency resulted in reduced suppressive ability of Tfr cells.
Diminished suppression of GC formation by transfer of Blimp1-deficient Tfr cells into EAMG mice
Transfer of negative control Tfr cells significantly reduced the size of the spleen and the size of GCs in the spleen and lymph node compared with transfer of Blimp1-deficient Tfr cells (Fig. 8a-c) . GL7 is the marker of B cells in GCs. In our study, we detected the expression of GL7 in the spleen and lymph nodes harvested from the three groups. We demonstrated that activated B cells in GCs of mice treated with Blimp1-deficient Tfr cells were significantly more than in the negative control Tfr-cell-treated group (Fig. 9) . Finally, we explored the possible mechanisms of diminished suppression of GC formation by transfer of Blimp1-deficient Tfr. By 15 days after first transfer, B cells were purified with magnetic beads from spleens of the different treatment groups, and B-cell lysates were analysed by Western blot analysis for several signalling axes. Our results demonstrated that p-AKT activation was significantly dampened in splenic B cells from the Blimp1-deficient Tfr-treated mice compared with that in the negative control Tfr group (Fig. 8d) . We failed to find a difference in the signal pathways of p-MAPK between the two groups (Fig. 8e) .
Discussion
An imbalance between Tfr cells and Tfh cells has been observed in autoimmune diseases. 16, [19] [20] [21] [22] 31 Decreased numbers of Tfr cells have been confirmed in EAMG and in patients with myasthenia gravis. 18, 32, 33 However, little is known about how the Tfr cells function. Tfr cells express high amounts of the prototypic Tfh genes Cxcr5, Cxcl13, Icos, Bcl6 and Pdcd1. 24 However, Tfr cells more closely resembled Treg cells than Tfh cells. 18, 24, 26, 27, 31, 33 Blimp1 is required to control the numbers of Tfr cells in the GC. 24 In our study and published data, deficiency of Blimp1 could increase the proportion of Tfr cells. 24 If lack of Blimp1 results in greater suppressive ability of Tfr cells, Blimp1 will become an important target for the treatment of myasthenia gravis.
Blimp1, an essential regulator of T-cell homeostasis and activation, controls T-cell proliferation and apoptosis. [28] [29] [30] Loss of Blimp1 led to expansion of CD4 + T cells, which were due to diminished activation-induced cell death. 28 However, the function of Blimp1 in Treg cells remains controversial. 28, 30 Kallies et al. reported that Blimp1-deficient Treg cells are present and functional in in vitro suppression assay and an in vivo model. 28 Meanwhile, Martins et al. found Blimp1-deficient Treg cells were defective in blocking the development of colitis in vivo. 30 In our study, we found that Blimp1-deficient Tfr cells are faulty in the suppression of activation and antibody production by B cells in vitro and protecting against EAMG in vivo, which was consistent with the study of Martins et al.
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It has been reported that Tfr cells from the blood are potent at inhibiting Tfh cell-mediated production of antibody, even when relatively few Tfr cells were transferred. 26, 31 Our data demonstrate that in EAMG mice, adoptive transfer of Tfr cells could regulate antibody production and GC formation by preferential expansion of negative regulatory cells (Tfr cells, Treg cells and Th2 cells) relative to inflammatory cells (Tfh cells, Th1 cells and Th17 cells) in vivo. Blimp1-deficient Tfr cells attenuated antibody production in vivo to a lesser extent than did negative control Tfr cells. Furthermore, we explored how modulation of Tfr cells was used therapeutically to protect immunity and inhibit autoimmune disease. Mitogen-activated protein kinases are essential in orchestrating a variety of cellular processes such as changes in cell proliferation, differentiation and survival. 34 They are present and active in most cell types and respond to a range of stimuli including growth factors, cytokines and oxidative stress. [35] [36] [37] We failed to find abnormal activation of the MAPKs signalling pathway in B cells of EAMG mice. The phosphoinositide 3-kinase-AKT pathway is an important signalling pathway that regulates the growth, proliferation and survival of lymphocytes. Abnormalities in this pathway are sufficient to alter lymphocyte homeostasis. 38, 39 It has been reported that mesenchymal stem cell transplantation suppressed abnormal activation of AKT/GSK 3b signalling pathway in T cells from mice in a mouse model of systemic lupus erythematosus. 40 Several recent studies showed that abnormal activation of the AKT signalling pathway was associated with the development, activation and proliferation of B cells. 41, 42 In line with these reports, our results showed that transfer of Tfr cells could inactivate AKT by down-regulating the phosphorylation of AKT in the B cells from the spleen of EAMG mice to a greater extent than Blimp1-deficient Tfr cells in vivo. Taken together, Tfr cells are potent suppressors of immunity and are controlled by Blimp1.
Our work has identified that Blimp1 is essential for the suppression of Tfr cells in vitro and in vivo. We have also demonstrated that Tfr cells could inhibit antibody production by down-regulating the phosphorylation of AKT in the B cells of the spleens of EAMG mice, to a greater extent than Blimp1-deficient Tfr cells. Our data provide a basis for further work to elucidate the function of Tfr cells.
